Lantheus Holdings, Inc.
No SEC Form 4 filings for $LNTH in the last 30 days.
Lantheus Holdings (NASDAQ: LNTH) reported Q2 CY2026 revenue of $388.2 million, up 2.7% year on year, ahead of Wall Street expectations. Non-GAAP adjusted EPS was $1.55, 18.9% above consensus. The article also cites adjusted operating margin of 31% and analyst expectations for revenue to decline 3.2% and full-year EPS to fall from $5.95 to $5.55.
Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lantheus Reports Second Quarter 2026 Financial Results • Worldwide revenue of $388.2 million in the second quarter of 2026 • GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 • Ad
Lantheus Holdings (NASDAQ: LNTH) is set to report Q2 results Thursday before the bell. The article notes it beat prior-quarter revenue expectations with $377.3 million revenue, up 1.2% YoY, but missed full-year revenue guidance expectations. For the upcoming quarter, analysts expect revenue down 4.7% YoY. LNTH shares are down 1.8% over a month; average analyst price target is $107.22 vs $100.97.
Over the past 7 days, alphai's AI scored 10 news stories mentioning LNTH (Lantheus Holdings, Inc.). Coverage has skewed bullish: 7 bullish, 3 neutral, and 0 bearish.
Recent LNTH coverage spans mergers & acquisitions, earnings and corporate actions.
Beat on revenue and adjusted EPS supports near-term sentiment, but the article flags expected revenue and EPS declines over the next 12 months.
The merger terms and suspension of 2026 guidance create a near-term repricing catalyst and shift the trade from fundamentals to deal-risk and CVR optionality.
Earnings timing is the main tradable element, with the article highlighting a revenue decline expectation and recent revenue-miss history.
Material take-private M&A terms with a defined per-share price and milestone-linked CVRs, likely driving near-term spread and deal-risk trading.
Deal terms and take-private structure create a near-term valuation floor and a catalyst for spread compression, subject to regulatory and shareholder approvals.
alphai scores every news story that mentions LNTH with an AI model for sentiment and relevance, and aggregates insider trades from Lantheus Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lantheus Holdings (NASDAQ: LNTH) reported Q2 CY2026 revenue of $388.2 million, up 2.7% year on year, ahead of Wall Street expectations. Non-GAAP adjusted EPS was $1.55, 18.9% above consensus. The article also cites adjusted operating margin of 31% and analyst expectations for revenue to decline 3.2% and full-year EPS to fall from $5.95 to $5.55.
5 min readLantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lantheus Reports Second Quarter 2026 Financial Results • Worldwide revenue of $388.2 million in the second quarter of 2026 • GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 • Ad
6 min readLantheus Holdings (NASDAQ: LNTH) is set to report Q2 results Thursday before the bell. The article notes it beat prior-quarter revenue expectations with $377.3 million revenue, up 1.2% YoY, but missed full-year revenue guidance expectations. For the upcoming quarter, analysts expect revenue down 4.7% YoY. LNTH shares are down 1.8% over a month; average analyst price target is $107.22 vs $100.97.
3 min readCurium US will buy all outstanding shares of Nasdaq-listed Lantheus for $102.50 per share at closing, plus non-transferable CVRs worth up to $12.00 more if 2030 milestones are met, for up to $114.50 total. The offer is a 38% premium to Lantheus’ 60-day VWAP. Board approved unanimously; deal expected to close in H1 2027.
6 min readCurium, backed by CapVest Partners, agreed to buy Nasdaq-listed Lantheus in an all-cash deal worth up to about $8bn. Curium will pay $102.50 per share at closing plus non-transferable CVRs up to $12.00 per share, totaling $114.50. The offer includes premiums of 29% to 38% versus recent averages and needs regulatory and shareholder approvals, expected to close in H1 2027.
4 min readLantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 d167446dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 A GREEMENT AND P LAN OF M ERGER AMONG C URIUM U S H OLDINGS LLC, C OCO M ERGER S UB I NC . AND L ANTHEUS H OLDINGS , I NC . DATED AS OF A UGUST 3, 2026 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.1 The Merger 2 Secti
6 min readTD Cowen downgraded Lantheus Holdings (LNTH) to Hold from Buy and cut its price target to $102.50 from $110.00. Analyst Tara Bancroft said the Curium deal is fair and sees >50% odds of most contingent value milestones, but less optimism on the top PSMA PET tier. The stock trades near $102.03. Separately, the FDA issued a Complete Response Letter for LNTH-2501.
4 min readLantheus (LNTH) said it agreed to be acquired by Curium, backed by CapVest, for up to $8 billion. Curium US will buy all LNTH shares for $102.50 cash plus non-transferable Contingent Value Rights up to $12 per share tied to milestones through 2030. Total up to $114.50 per share, a 38% premium. Deal expected to close in 1H 2027.
4 min readReuters reports Curium will buy Lantheus Holdings in a deal worth up to $8 billion. Lantheus shareholders will receive $102.50 per share in cash, plus rights for up to $12 more per share if sales targets are met by 2030. Total $114.50 per share is a ~14.9% premium to $99.64. Deal expected to close in H1 2027.
6 min readCurium and Lantheus (NASDAQ: LNTH) announced a definitive merger agreement. Curium US will acquire all Lantheus shares for $102.50 cash per share at closing plus non-transferable CVRs worth up to $12.00 per share tied to commercial milestones through 2030. Total value up to about $8.0 billion, a 38% premium to 60-day VWAP.
6 min read
